Home › Myelofibrosis › Washington › Seattle
Myelofibrosis clinical trials in Seattle, WA
12 studies for Myelofibrosis are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
RecruitingPhase 3
- Fred Hutch Cancer Research, Seattle
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
RecruitingPhase 3
- University of Washington, Seattle
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RecruitingPhase 2
- GSK Investigational Site, Seattle
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
RecruitingPhase 1
- Site US22, Seattle
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
- University of Washington, Seattle
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RecruitingPhase 1/2
- University of Washington - Fred Hutchinson Cancer Center, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RecruitingPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Seattle
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RecruitingPhase 3
- Fred Hutchinson Cancer Centre, Seattle
Myelofibrosis trials in other cities
- New York City, NY21 studies
- Houston, TX20 studies
- Boston, MA13 studies
- Durham, NC13 studies
- Columbus, OH12 studies
- Tampa, FL11 studies
- Nashville, TN11 studies
- Miami, FL11 studies
- Salt Lake City, UT11 studies
- Ann Arbor, MI10 studies
- Atlanta, GA10 studies
- Baldwin Park, CA10 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer55 studies
- Cancer (all types)48 studies
- Prostate Cancer45 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Breast Cancer37 studies
- Colorectal Cancer35 studies
- Lung Cancer34 studies
- Ovarian Cancer29 studies
- Pancreatic Cancer22 studies
- Multiple Myeloma22 studies
- Acute Lymphoblastic Leukemia22 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.